SLNO Soleno Therapeutics Inc

Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

REDWOOD CITY, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Healthcare Conference on Thursday, December 4, 2025, at 9:00 AM Eastern Time.

A and replay of the presentation will be available in the Investors section on the Company’s website at .

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The Company’s first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit .

Corporate Contact:

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578



EN
24/11/2025

Underlying

SLNOSoleno Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Soleno Therapeutics Inc

 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics to Participate in Upcoming Conferences

Soleno Therapeutics to Participate in Upcoming Conferences REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February and March: Guggenheim Emerging Outlook: Biotech Summit 2026Presentation Date: Thursday, February 12, 2026 at 11:30 AM ETPresentation Format: Fireside ChatWebcast: Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation Date...

January 29, 2026 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Fu...

Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results REDWOOD CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced select preliminary financial and operating results for the fourth quarter and full-year 2025: Preliminary unaudited full-year 2025 net revenue related to U.S. sales of VYKAT™ XR since second quarter launch expected to be in a range of $189 million to $191 million.Preliminary unaudited ...

January 12, 2026 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Announces Publication of Results from Pivotal Stud...

Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a publication in the peer-reviewed Journal of Clinical Endocrinology and Metabolism (JCEM). The paper, titled, “Diazoxide Choline Extended-Release Tablets in Prader-Willi Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Withdraw...

January 5, 2026 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Announces the Passing of Board Member William G. H...

Soleno Therapeutics Announces the Passing of Board Member William G. Harris REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today regrets to announce the passing of William G. “Bill” Harris, who served as a valued member of Soleno’s Board of Directors since June 2014. Mr. Harris also served as Chairman of the Audit Committee. “I have known Bill for many years, and always viewed him as a person of integrity, who exhibited pragmatism and a...

December 3, 2025 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics to Present at the Piper Sandler 37th Annual Health...

Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference REDWOOD CITY, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Healthcare Conference on Thursday, December 4, 2025, at 9:00 AM Eastern Time. A and replay of the presentation will be available in the Investors section on the Company’s we...

November 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch